Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Topics

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Health - The New York Times - 2 days ago
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Business - MarketWatch - November 11
AbbVie shares tumble after schizophrenia drug disappoints
Business - Financial Times - November 11
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Business - MarketWatch - November 14
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals
Business - MarketWatch - 2 days ago
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
Business - MarketWatch - November 12
Chancellor and BoE governor call for UK to rebuild ties with EU
Business - Financial Times - November 14
Britain’s bold plan to create super funds
Business - Financial Times - November 14
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Business - MarketWatch - November 4
Novartis Lifts Guidance Again After Key Drugs Help Results
Business - The Wall Street Journal - October 29
Rapper Young Thug pleads guilty to gang, drug and gun charges almost a year after opening statements in trial
Entertainment - ABC News - October 31
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction
Business - CNBC - October 30
European committee takes a second look at Alzheimer's drug and now says it should be approved
Health - ABC News - November 14
US flights to Haiti halted for month after attacks
Top stories - BBC News - November 13
'Never': Jimmy Lai denies foreign collusion in landmark trial
Top stories - BBC News - November 20
Over 100 sentenced for drug-related crimes in Belgium’s largest trial
World - Financial Times - October 29
An Australian on trial for drugs in Japan says she's the victim of a romance scam
World - ABC News - November 18
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Health - ABC News - October 31
'I didn’t think there was cause to shoot Chris Kaba' – police watchdog lead defends sending case to CPS
Top stories - BBC News - November 4
Oil ends down on the day, up for the week on conflicting supply-demand prospects
Business - MarketWatch - November 8
Mozambique’s Main Port Halts Taking Cargo After Election Unrest
World - Yahoo News - November 6
Idaho's plan to execute serial killer halted after botched attempt
Top stories - CBS News - November 7
Airlines halt flights to Haiti after plane hit by gunfire
World - The Guardian - November 12
U.S. airlines halt travel to Haiti after shots fired at planes
Top stories - CBS News - November 12
U.S. halts flights to Haiti after 3 planes hit by gunfire
Top stories - CBS News - November 13
Doctors Without Borders halts operations in Haiti's capital after escalation in violence
Top stories - NBC News - November 20
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Business - MarketWatch - October 30
Saquon Barkley didn't question controversial fumble that resulted in Jaguars TD: 'I knew it was gonna stand'
Sports - CBS Sports - November 4
Mike Tyson vs. Jake Paul undercard results: Katie Taylor gets controversial win to retain vs. Amanda Serrano
Sports - CBS Sports - November 16
Pair sentenced for drug supply after teenager died
Top stories - BBC News - November 4
Dozens jailed in drug smuggling mega-trial: "Your honor, I played, I lost."
Top stories - CBS News - October 29
‘Was I drugged and raped? I’ll never know’: partners of accused share fears at Pelicot trial
World - The Guardian - November 8
Pelicot trial: young vineyard worker proposed drugging and raping his own mother
World - The Guardian - November 15
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Business - MarketWatch - November 19
Microsoft's stock has worst day in two years after disappointing forecast
Business - CNBC - October 31